Bristol-Myers Squibb
2021-12-07 2:55 pm
| Sydney
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.